Translational Medicine

Uckun, Transl Med 2013, 3:1
http://dx.doi.org/10.4172/2161-1025.1000e118

Editorial Open Access

Monoclonal Antibody (mAb)-Based Biotherapy Options for B-lineage Non-Hodgkin's Lymphoma (NHL)

Fatih M Uckun*

Children's Center for Cancer and Blood Diseases and Norris Comprehensive Cancer Center

In recent years new biotherapy options have emerged for patients with B-lineage Non-Hodgkin's Lymphoma (NHL). A series of novel mAbs with specificity for a variety of surface antigens are currently under evaluation. These include anti-CD20 mAb (ofatumumab, veltuzumab, ocrelizumab, ocaratuzumab, obinutuzumab, ublituximab), anti-CD19 mAb (MOR208), anti-CD22 mAbs (epratuzumab, inotuzumab ozogamicin) and anti-CD16/CD30 mAb (TandAb® AFM13) [1-12].

Targeting CD20

Rituximab (RTX, Rituxan, Roche/Biogen Idec) is the best known anti-CD20 mAb and has been used both for biotherapy of patients with B-lineage NHL who experience a recurrence of their disease after frontline therapy as well as for frontline treatment of B-lineage NHL patients who are at high risk to experience a recurrence after chemotherapy. Combination of RTX with chemotherapy (e.g. RTX + CHOP) has improved treatment outcomes and is now considered the standard of care for many forms of NHL, including diffuse large B-cell lymphoma (DLBCL) [1]. However, resistance to RTX does occur and compromises the outcome of B-lineage NHL patients receiving RTX as part of their treatment plan [2]. Bioengineering has been applied to generate new anti-CD20 mAb to overcome RTX resistance [3-8]. Ofatumumab (OFA, Genmab AC and GlaxoSmithKline) is a human mAb that targets unique epitopes of the CD20 antigen [4]. OFA is used for biotherapy of patients with well-differentiated small lymphocytic lymphoma/chronic lymphocytic leukemia (CLL) who do not respond to fludarabine and alemtuzumab (Campath 1-H). Veltuzumab (Immunomedics, Inc.) is a humanized, type I (i.e., RTX-like as opposed to tositumomab-like) anti-CD20 IgG1 mAb, with higher affinity to CD20 and improved complement-dependent cytotoxicity (CDC) against B-lineage NHL cells. This mAb is also being evaluated in combination with the humanized anti-CD74 antibody milatuzumab [9]. Ocrelizumab (Roche/Biogen Idec) is also a type I humanized mAb that has enhanced potency against B-lineage NHL cells as well as improved ability to cause antibody-dependent cell-mediated cytotoxicity (ADCC) against NHL than RTX [5]. Both antibodies are currently being evaluated in early phase clinical trials. Ocaratuzumab (Mentrik Biotech, LLC) is a type I humanized mAb with increased affinity for CD20 as well as low affinity FcγRIIIa receptor involved in ADCC. It has shown promising early activity in a Phase I clinical study [6]. Obinutuzumab (Genmab AC) is a type II humanized anti-CD20 mAb that has shown promising preclinical as well as early clinical activity against RTX-resistant B-lineage NHL. It is now being compared to RTX in randomized clinical trials [7]. Ublituximab (TG Therapeutics, Inc) is a chimeric mAb with superior ADCC activity that showed very promising activity against RTX-resistant NHL in early clinical testing [8].

Targeting Surface Antigens Other than CD20

MOR208 (MorphoSys AG) is a new anti-CD19 mAb, which was well-tolerated and showed promising biologic activity in early clinical testing [10]. Epratuzumab (Immunomedics, Inc.) is a humanized anti-CD22 mAb that showed single agent clinical activity in NHL patients. TandAb® AFM13 (Affimed Therapeutics AG) is specifically designed to treat CD30-antigen NHL. It binds to both CD30 on malignant cells and CD16 on natural killer cells and mediates ADCC. This bispecific mAb showed a promising safety and activity profile in early clinical evaluation [11,12].

Further development of some of these new mAb against CD20 or non-CD20 target antigens may overcome RTX resistance and thereby provide the foundation for therapeutic innovations with unprecedented clinical activity against poor prognosis NHL.

References

1. Hsu JW, Dang NH (2013) The role of monoclonal antibodies in the treatment of lymphomas. Expert Opin Biol Ther 13: 227-239.
2. Cartron G, Trappe RU, Solal-Céligny P, Hallek M (2011) Interindividual variability of response to rituximab: from biological origins to individualized therapies. Clin Cancer Res 17: 19-30.
3. Cang S, Mukhi N, Wang K, Liu D (2012) Novel CD20 monoclonal antibodies for lymphoma therapy. J Hematol Oncol 5: 64.
4. Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, et al. (2006) The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 177: 362-371.
5. Morschhauser F, Marlton P, Vitolo U, Linden O, Seymour JF, et al. (2010) Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Ann Oncol 21: 1870-1876.
6. Forero-Torres A, de Vos S, Pohlman BL, Pashkevich M, Cronier DM, et al. (2012) Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma. Clin Cancer Res 18: 1395-1403.
7. Obinutuzumab (GA101) Significantly improved progression-free survival in people with chronic lymphocytic leukemia (CLL) (2013) Genentech news release, South San Francisco.
8. Deng C, Amengual JE, Schreeder MT, Clark-Garvey S, Patterson M, et al. (2013) A Phase I dose-escalation trial of ublituximab (TG-1101), a novel anti-CD20 monoclonal antibody (mAb), for rituximab relapsed/refractory B-cell lymphoma patients. 2013 ASCO Annual Meeting. J Clin Oncol 31: Abstract 8575.
9. Christian B, Alinar Li, Jones JA, Benson Jr DM, Flynn JM, et al. (2011) Results of a Phase I study of Milatuzumab, a humanized anti-CD74 antibody, and Veltuzumab, a humanized anti-CD20 antibody, in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma. 53rd ASH Annual Meeting, San Diego, CA, Abstract 3707.
10. Woyach JA, Awan F, Flinn IW, Enoch R, Foster PA, et al. (2011) Final results of a Phase I study of the Fc engineered CD19 antibody XmAb®5574 (MOR00208) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). 54th ASH Annual Meeting, San Diego, CA, Abstract 2894.
11. Tomblyn MB, Witzig TE, Himelstein AL, Elstrom R, Kio EA, et al. (2011) Combination therapy targeting two different antigens with anti-CD22

***Corresponding author:** Fatih M Uckun, Children's Center for Cancer and Blood Diseases and Norris Comprehensive Cancer Center, USC Keck School of Medicine, Los Angeles, CA 90027, USA, E-mail: uckun@usc.edu

Received July 15, 2013; **Accepted** July 17, 2013; **Published** July 19, 2013

Citation: Uckun FM (2013) Monoclonal Antibody (mAb)-Based Biotherapy Options for B-lineage Non-Hodgkin's Lymphoma (NHL). Transl Med 3: e118. doi:10.4172/2161-1025.1000e118

radioimmunotherapy and anti-CD20 immunotherapy in non-Hodgkin lymphoma (NHL): Phase I results. 54th ASH Annual Meeting, San Diego, CA, Abstract 3680.

12. Engert A (2013) A Phase I study of bisepecific CD30/CD16A TandAb antibody AFM13 in patients with relapsed or refractory Hodgkin lymphoma. The 12th International Conference on Malignant Lymphoma, Lugano, Switzerland, Abstract 042.

Citation: Uckun FM (2013) Monoclonal Antibody (mAb)-Based Biotherapy Options for B-lineage Non-Hodgkin's Lymphoma (NHL). Transl Med 3: e118. doi:10.4172/2161-1025.1000e118